Amikacin

Amikacin

Clinical data
Pregnancy category	AU: D US: C (Risk not ruled out)
Routes of administration	Intramuscular, intravenous
ATC code	D06AX12 (WHO) J01GB06 (WHO), S01AA21 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Protein binding	0-11%
Elimination half-life	2-3 hours
Excretion	Renal
Identifiers
IUPAC name (2S)-4-amino-N-[(2S,3S,4R,5S)-5-amino-2- [(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy- 6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R, 4S,5R,6R)-6-(aminomethyl)-3,4,5-trihydroxy- oxan-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy- butanamide
CAS Number	37517-28-5
PubChem CID	441188
DrugBank	APRD00550
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H43N5O13
Molar mass	585.603 g/mol

WikiDoc Resources for Amikacin
Articles
Most recent articles on Amikacin Most cited articles on Amikacin Review articles on Amikacin Articles on Amikacin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Amikacin Images of Amikacin Photos of Amikacin Podcasts & MP3s on Amikacin Videos on Amikacin
Evidence Based Medicine
Cochrane Collaboration on Amikacin Bandolier on Amikacin TRIP on Amikacin
Clinical Trials
Ongoing Trials on Amikacin at Clinical Trials.gov Trial results on Amikacin Clinical Trials on Amikacin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Amikacin NICE Guidance on Amikacin NHS PRODIGY Guidance FDA on Amikacin CDC on Amikacin
Books
Books on Amikacin
News
Amikacin in the news Be alerted to news on Amikacin News trends on Amikacin
Commentary
Blogs on Amikacin
Definitions
Definitions of Amikacin
Patient Resources / Community
Patient resources on Amikacin Discussion groups on Amikacin Patient Handouts on Amikacin Directions to Hospitals Treating Amikacin Risk calculators and risk factors for Amikacin
Healthcare Provider Resources
Symptoms of Amikacin Causes & Risk Factors for Amikacin Diagnostic studies for Amikacin Treatment of Amikacin
Continuing Medical Education (CME)
CME Programs on Amikacin
International
Amikacin en Espanol Amikacin en Francais
Business
Amikacin in the Marketplace Patents on Amikacin
Experimental / Informatics
List of terms related to Amikacin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. Amikacin works by binding to the bacterial 30S ribosomal subunit, causing misreading of mRNA and leaving the bacterium unable to synthesize proteins vital to its growth.

Administration

Amikacin may be administered once or twice a day but must be given by the intravenous or intramuscular route, which tends to be painful. There is no oral form available. Dosage must be adjusted in people with kidney failure.

Uses

Amikacin is most often used for treating severe, hospital-acquired infections with multidrug resistant Gram negative bacteria such as Pseudomonas aeruginosa, Acinetobacter, and Enterobacter.

Amikacin may be combined with a beta-lactam antibiotic for empiric therapy for people with neutropenia and fever.

Side effects

Side effects of amikacin are similar to other aminoglycosides. Kidney damage and hearing loss are the most important effects. Because of this potential, blood levels of the drug and markers of kidney function (creatinine) may be monitored.

References

• Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1999 May;74(5):519-28. Review. PMID 10319086